1. The DOJ was investigating Mylan after discovering the company had classified the Mylan-brand EpiPen as a generic drug.
2. The settlement has no language implying Mylan committed any wrongdoings.
3. The EpiPen was classified as a generic drug before Mylan acquired rights to the product in 2007.
4. Through the settlement, Mylan will resolve all the claims against it by the DOJ. The two entities will work together to finalize the settlement.
5. Mylan’s CEO Heather Bresch said the settlement is “another important step” to bringing a resolution to matters surrounding the EpiPen.
6. Mylan is in the process of launching a generic version of the EpiPen.
7. On Mylan’s Sept. 30 quarterly earnings it will include a pre-tax charge of $465 million.
8. Mylan will report its third quarter earnings on a webcast on Nov. 9.
More coding, billing and collections news:
CMS Acting Administrator calls ACA a ‘great disruption’ —4 things to know
Three strategies for optimizing your ambulatory network
Number of small businesses in Kentucky offering insurance decreases: 3 takeaways
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.